Biodexa Pharmaceuticals Enrolls 100 Patients In Its Registrational Phase 3 Serenta Trial Of eRapa In Familial Adenomatous Polyposis; Trial Is Recruiting At 29 Clinical Sites In U.S., Canada And Europe And Is Expected To Be Initiated Shortly
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "the Company"), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of
Share
Why It Matters
Biodexa started testing a new medicine called eRapa in 100 patients. Watch to see if the medicine works well and stays safe.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.